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Rotaviruses were discovered in the 1960s
in animals and in the 1970s in humans;
the latter discovery was made by an in-
trepid group who performed duodenal bi-
opsies on children with acute gastroenter-
itis (AGE) [1]. By the late 1970s, data
already clearly indicated that rotavirus was
the cause of the annual winter peak of
AGE affecting young children, as well as
a frequent cause of severe gastroenteritis
in various animal species (e.g., [2–5]). Use
of the retrospectroscope clarified or left as
tantalizing the suggestion that rotaviruses
were the cause of the annual “winter vom-
iting syndrome” first described in children
in 1910 in Japan [6] and in 1929 in the
United States [7]. The recognition of that
winter peak was a result of improved water
and sewage handling that markedly re-
duced exposure to bacterial and parasitic
pathogens but not to the common viral
pathogens.
Many studies have been conducted to
examine the burden of rotavirus disease.
Most of these have been cross-sectional in
design, have documented the high (usual-
ly 30%–60%) frequency of rotavirus de-
tection among children hospitalized with
AGE, and have found that the more in-
tense the severity of illness, the more fre-
quently rotavirus is detected. Longitudi-
nal, cohort studies of rotavirus disease
have been fewer in number, and most of
these have suffered from study design is-
sues, such as enrollment of subjects at an
age later than birth, resulting in infections
at an early age being missed, or assessment
of rotavirus infection only by detection of
virus excreted in stool, when a large frac-
tion of rotavirus infections are detected
not by routinely applied assays but by se-
roresponse. Population-based studies have
been even less frequently undertaken, and
most such studies have depended on in-
direct measures of rotavirus disease—
namely, the assignment of International
Classification of Diseases codes, along with
occurrence of the codes within age, season,
and list position (within a list of assigned
International Classification of Diseases
codes) distributions [8].
Direct, active surveillance always is pre-
ferred to indirect measures in attempts to
identify cases of any disease. In the studies
reported in this supplement to the Journal
of Infectious Diseases, conducted by Pierre
Van Damme and his colleagues in Europe
[9–12], several laudable features were part
of the study design: establishment of de-
fined geographic surveillance regions with
known populations, active surveillance at
treatment sites for different acuities of
AGE and for that fraction of cases caused
by rotavirus, application of the same study
protocol within different countries at the
same time, and broad probing for factors
affecting the cost of the illness and care
for it.
Perhaps the authors expected that the
cumulative results of this effort would lead
to data enabling a unified, simplified ex-
trapolation, to Europe or to western Eu-
rope, of the burden of the syndrome and
that fraction caused by rotavirus. The sur-
prise, for me, is the variance that was ob-
served in the results: multifold differences
among study regions in the incidence of
AGE of all causes in the same age group,
similar differences among regions in the
incidence of AGE attributable to rotavirus,
major differences in the prevalence of dif-
ferent rotavirus serotypes in study regions
not too far apart, and striking differences
in estimates of the cost of AGE as a syn-
drome and of AGE attributable to rota-
virus. The least unexpected of these results
are the differences in rotavirus serotype
prevalence by region. We have known from
prior studies that rotavirus serotype dis-
tribution changes every 1–2 years in some
regions, but a single serotype also may be
predominant for as many as 10 years in a
region.
These differences in disease incidence
were, perhaps, not unexpected, because we
still have major differences within coun-
tries with well-developed infrastructure in
water and sewage handling and in living
conditions that affect exposure to enteric
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pathogens. Particular differences that af-
fect gastroenteritis disease burden include
the presence and amount of sewage han-
dling through septic tanks, practices for
the pretreatment of sewage before dis-
charge, types and degree of contamination
of drinking source waters (lakes and riv-
ers in comparison with aquifers accessed
through deep or shallow wells and the soil
and rock formations above them), differ-
ences in close exposures to animals that
can be a source of human infections, and
the degree of crowding in living condi-
tions. For the latter, think only of dif-
ferences in the “environmental quality”
among and within child care centers, nurs-
ing homes, and hospitals: food handlers
who do not wash their hands or wear
mandated gloves; changing of soiled dia-
pers and bed clothes and their disposal
and cleaning at inappropriate locations,
such as in kitchens; and the use of con-
taminated water for the washing of food.
It also is possible that, just as physicians
differ in the frequency of referral of pa-
tients from the office setting to the emer-
gency department and/or hospital setting,
parents are also likely to differ in their
sense of a need for medical care for their
child’s gastroenteritis episode. There are
hints that the study populations may have
differed to large degrees; for example, the
rate of parents speaking a language not
native to the study region was 41% at one
study site, whereas this rate was much
lower (!10%) elsewhere.
The limitations of the studies perhaps
are overemphasized by the authors. It is
important to emphasize the positive as-
pects: large, predefined study populations;
active surveillance at treatment sites in-
tended to care for differing acuities of dis-
ease; and uniform definitions and analy-
sis factors. The authors properly restate,
on the basis of their work, that rotavirus
is a significant cause of an expensive po-
tentially vaccine-preventable disease in
Europe. Their results provide useful in-
formation needed to design surveillance
protocols for assessing vaccine effective-
ness. It is worth noting that Europe now
has 2 licensed rotavirus vaccines and that
these 2 vaccines differ greatly in their ap-
proaches to the induction of protective
immunity. One vaccine is monovalent, the
other pentavalent. Although phase 3 stud-
ies [13, 14] have given similar overall ef-
ficacy results, differences were found in
serotype-specific efficacy that would be ex-
pected from the differences in antigenic
composition of the vaccines. The 2 vac-
cines also differ in the number of studied
doses. I encourage the authors, in a follow-
up report, to consider the fraction of vac-
cine-preventable disease by study region
and to study the efficacy of the 2 licensed
vaccines. It will be important, going for-
ward, to continue to measure accurately
the differences in effectiveness related to
the number of vaccine doses and serotype-
specific protection. In this regard, the var-
iability in observed rates of illness, patterns
of treatment related to physician referral
practices, and serotype distribution in
these studies with a common, robust study
protocol suggest that ongoing surveillance
will need careful design. Active surveil-
lance is also likely to trump indirect sur-
veillance in this undertaking.
The observation of significant differ-
ences among age distributions of prevail-
ing serotypes in the different study regions
deserves some comment. When examined
over multiple years and/or over different
regions, rotavirus serotypes do not show
significant differences in age distribution
among affected children; such findings
have falsely led to the conclusion that ro-
tavirus serotypes never differ in age dis-
tribution. What should we think when
faced with the REVEAL Study findings of
marked differences in serotype distribu-
tion by age? Distributions of rotavirus se-
rotypes do differ within a single region,
across ages from one season to the next,
and among widely separated regions in the
same rotavirus season [15, 16]. The pat-
terns observed result from the introduc-
tion of serotypes that are new to a region;
these serotypes first appear within cities
and then spread over a 2- to 3-year period
to the surrounding rural regions. Spread
of the new serotype across broad geo-
graphic regions may take years, unlike in-
fluenza and more like cholera [17, 18].
When the epidemic serotype enters a pop-
ulation, its age distribution is broader than
that of established, endemic serotypes, af-
fecting a greater percentage of young in-
fants whose mothers lack recent exposure
to the serotypes and of older children and
adults whose acquired immunity is insuf-
ficient to protect against illness caused by
the epidemic type. These patterns have
important implications for the design of
appropriate disease and serotype surveil-
lance after the introduction of mass
immunization.
We can look forward to a reduced bur-
den of rotavirus disease, now that we have
new vaccines to prevent infection and ill-
ness. The success of that intervention
strategy will be measured by the collection
of accurate data. Van Damme and col-
leagues have provided a model from the
prelicensure period for how to consider
such studies now that mass vaccination
has begun.
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